NCT02994407 - Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 15, 2018

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa pegol

"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."

Trial Locations (19)

1090

Novo Nordisk Investigational Site, Vienna

10249

Novo Nordisk Investigational Site, Berlin

11000

Novo Nordisk Investigational Site, Belgrade

11070

Novo Nordisk Investigational Site, Belgrade

21000

Novo Nordisk Investigational Site, Novi Sad

23507

Novo Nordisk Investigational Site, Norfolk

32827

Novo Nordisk Investigational Site, Orlando

44093

Novo Nordisk Investigational Site, Nantes

44106

Novo Nordisk Investigational Site, Cleveland

45404

Novo Nordisk Investigational Site, Dayton

47051

Novo Nordisk Investigational Site, Duisburg

48823

Novo Nordisk Investigational Site, East Lansing

52242

Novo Nordisk Investigational Site, Iowa City

53226

Novo Nordisk Investigational Site, Milwaukee

66421

Novo Nordisk Investigational Site, Homburg

29425-0001

Novo Nordisk Investigational Site, Charleston

A 6020

Novo Nordisk Investigational Site, Innsbruck

160 0023

Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo

167-0035

Novo Nordisk Investigational Site, Tokyo